Parkinson’s disease, characterized by progressive dopamine neuron loss, leads to motor deficits such as bradykinesia and rigidity, as well as nonmotor symptoms like cognitive decline and depression. While L-DOPA alleviates motor symptoms, long-term use often results in side effects, including motor fluctuations and dyskinesias, as well as nonmotor (psychotic-like) side effects.

The largest analysis to date of patients taking GLP-1 receptor agonists (GLP-1RAs) has investigated their effects on nearly 175 diseases, and found that compared to three other classes of diabetes medications, individuals with a prescription for GLP-1RAs had a reduced risk of 42 diseases, and an increased risk of 19. The findings, which were published Jan. 20, 2025, in Nature Medicine, provide a comprehensive overview of GLP-1RAs’ effects.

Researchers from Cornell University are seeking protection for their invention of a low-cost artificial intelligence (AI)-based platform that analyses low resolution electrocardiogram data and/or photoplethysmography data to accurately and objectively assess pain.

Having 35 copies of the CAG triplet in the gene that causes Huntington’s disease is not a problem. Inheriting 40 could be a sign that goes unnoticed for decades, until reaching 80. From there, the process accelerates and neural death occurs when reaching 150 repeats. Huntington’s disease neurodegeneration is not determined by what, but by how much, according to a study conducted at the Broad Institute.